Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

BACKGROUND: Intestinal microbiota restoration can be achieved by complementing a subject’s perturbed microbiota with that of a healthy donor. Recurrent Clostridioides difficile infection (rCDI) is one key application of such treatment. Another emerging application of interest is reducing antibiotic-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Microbiome
Autors principals: Kwak, Suryang, Choi, JooHee, Hink, Tiffany, Reske, Kimberly A., Blount, Kenneth, Jones, Courtney, Bost, Margaret H., Sun, Xiaoqing, Burnham, Carey-Ann D., Dubberke, Erik R., Dantas, Gautam
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7457799/
https://ncbi.nlm.nih.gov/pubmed/32862830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40168-020-00907-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars